权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Potential clinical significance of newly identified substances as early atherosclerosis marker

新发现的物质作为早期动脉粥样硬化标志物的潜在临床意义

基本信息

批准号：
17590765
负责人：
MOCHIZUKI Seibu
金额：
$ 1.73万
依托单位：
JIKEI UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2005
资助国家：
日本
起止时间：
2005 至 2006
项目状态：
已结题

项目摘要

In the previous pilot study, we identified several substances, including two unknown one, in patients with coronary heart disease (CHD). Therefore, we assessed significance of these substances as early atherosclerosis marker in 185 patients with CHD by comparing 98 healthy volunteers. a-hydroxy butyric acid (HBA), palmitoleic acid, and palmitic acid were measured by GC-MS method. IL-6,hsCRP, adiponectin, slCAM-1,sVCAM-1,and sP-selectin were measured by enzyme-linked immunosorbant assay (ELISA).Results : α-HBA and palmitic acid were found to be significantly higher in CHD patients as compared with controls. Correlation analysis revealed that α-HBA correlated negatively with adiponectin and VCAM-1,but positively with palmitic acid, respectively. Palmitic acid showed a strong positive correlation with NEFA. Finally, we performed correlation analysis among all atherosclerosis markers. Firstly as expected, IL-6 and hsCRP strongly correlated. sVCAM-1 correlated positively with these inflammation markers as well as adiponectin and slCAM-1. Interestingly, NEFA correlated with all our newly identified substances and adiponectin do so with two of these (α-HBA and palmitoleic acid). Furthermore, these three substances correlated positively with each other.Conclusions : Our attempt resulted to find two newly identified substances (α-HBA and palmitoleic acid) to be increased in patients with coronary heart disease. Although these showed partial correlation with other already-reported atherosclerosis markers such as adiponectin, slCAM1, these substances could be new candidate for atherosclerosis markers.

在先前的初步研究中，我们确定了几种物质，包括两种未知的物质，在冠心病（CHD）患者。因此，我们评估了这些物质作为早期动脉粥样硬化标志物在185例冠心病患者中的意义，并与98名健康志愿者进行了比较。用GC-MS法测定了α-羟基丁酸（HBA）、棕榈油酸和棕榈酸的含量。采用酶联免疫吸附法（ELISA）检测血清IL-6、hsCRP、脂联素、sICAM-1、sVCAM-1、sP-选择素水平。相关分析显示，α-HBA与脂联素、VCAM-1呈负相关，与棕榈酸呈正相关。棕榈酸与NEFA呈强正相关。最后，我们对所有动脉粥样硬化标志物进行了相关性分析。首先，正如预期的那样，IL-6和hsCRP强烈相关。sVCAM-1与这些炎症标志物以及脂联素和sICAM-1正相关。有趣的是，NEFA与我们新发现的所有物质相关，脂联素与其中两种物质（α-HBA和棕榈油酸）相关。结论：我们的尝试发现两种新鉴定的物质（α-HBA和棕榈油酸）在冠心病患者中升高。虽然这些物质与其他已报道的动脉粥样硬化标志物如脂联素、sICAM 1存在部分相关性，但这些物质可能是动脉粥样硬化标志物的新候选者。

项目成果

期刊论文数量（11）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients

DOI：
10.1038/sj.ki.5002131
发表时间：
2007-05-01
期刊：
KIDNEY INTERNATIONAL
影响因子：
19.6
作者：
Frischmann, M. E.;Kronenberg, F.;Dieplinger, H.
通讯作者：
Dieplinger, H.

Metabolism of ApoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat.

持续喂食少量脂肪期间，肠道和肝脏来源的 ApoB 脂蛋白的代谢。

DOI：
发表时间：
2006
期刊：
J Lipid Res. 47
影响因子：
0
作者：
Shinohara T;Ueda A;Abe-Dohmae S.;Tsujita M.;Hayashi M.;Tsujita M. et al.;Hayashi M. et al.;Cuchel M;Frischmann ME;Mochizuki S;Cuchel M;Cuchel M;Frischmann ME;Mochizuki S;Nishiwaki M;Zheng C;Abe Y;Nishiwaki M;Zheng C
通讯作者：
Zheng C

Reduction in Cholesterol in Homozygous Familial Hypercholesterolemia with an Inhibitor of the Microsomal Triglyceride Transfer Protein.

使用微粒体甘油三酯转移蛋白抑制剂降低纯合子家族性高胆固醇血症中的胆固醇。

DOI：
发表时间：
2007
期刊：
New Engl. J. Med. 356
影响因子：
0
作者：
Oike;Y.;Akao;M.;Kubota;Y.;Suda;T.;Cuchel M
通讯作者：
Cuchel M

Human lecithin:cholesterol acyltransferase deficiency: in vivo kinetics of low-density lipoprotein and lipoprotein-X.

人卵磷脂：胆固醇酰基转移酶缺乏症：低密度脂蛋白和脂蛋白-X 的体内动力学。

DOI：
10.1161/01.atv.0000217910.90210.99
发表时间：
2006
期刊：
Arteriosclerosis, thrombosis, and vascular biology
影响因子：
0
作者：
Nishiwaki,Masato;Ikewaki,Katsunori;Bader,Giovanni;Nazih,Hassan;Hannuksela,Minna;Remaley,AlanT;Shamburek,RobertD;BrewerJr,HBryan
通讯作者：
BrewerJr,HBryan

Pravastatin prevents myocardium from ischemia-induced fibrosis by protecting vascular endothelial cells exposed to oxidative stress